Irogue Igbinosa, MD is a Maternal-Fetal Medicine fellow at Stanford University. She graduated from the University of Houston and earned her medical degree at Baylor College of Medicine. She subsequently completed her residency in Obstetrics and Gynecology Residency at Louisiana State University School of Medicine Baton Rouge. After residency, she was an AAMC-CDC Public Health Policy Fellow able to serve in the CDC Emergency Operations Center and contribute to research for health care providers regarding the management of the Zika virus in pregnant persons. Dr. Igbinosa's current research interests include severe maternal morbidity and mortality, health disparities and equity, anemia in pregnancy, infectious diseases, and clinical trials.
Iron deficiency anemia in pregnancy.
Current opinion in obstetrics & gynecology
2022; 34 (2): 69-76
PURPOSE OF REVIEW: Anemia in pregnancy is associated with increased maternal and neonatal morbidity. There is increasing awareness amongst obstetricians about the need to screen for iron deficiency anemia (IDA), as well as growing literature on diagnosis and treatment. This review aims to summarize causes, consequences, treatment, and evaluation of IDA in pregnancy.RECENT FINDINGS: National guidelines provide varying guidance on diagnosis and treatment of IDA in pregnancy. Serum ferritin is a helpful adjunct for the diagnosis of IDA. Oral iron remains an option for treatment; absorption is improved with every other day dosing and is effective for patients able to tolerate. Emerging studies on modern generations of intravenous (IV) iron demonstrate shorter infusion times and improved safety profiles. Notably, recent UK guidelines provide consideration for universal IV iron supplementation for treatment of anemia beyond 34 weeks of pregnancy.SUMMARY: Iron, in dietary, oral, and IV forms, has been found effective in resolving anemia in pregnancy. Pregnant people with IDA in the third trimester are more likely to benefit from IV iron. Future studies designed and powered to assess maternal and perinatal morbidity indicators and blood transfusion rates can strengthen recommendations.
View details for DOI 10.1097/GCO.0000000000000772
View details for PubMedID 35230991
Health Disparities in Antepartum Anemia: The Intersection of Race and Social Determinants of Health
MOSBY-ELSEVIER. 2022: S529-S530
View details for Web of Science ID 000737459401182
Editorial: How COVID-19 has affected maternal-fetal medicine and obstetrics?
Current opinion in obstetrics & gynecology
2021; 33 (5): 416-418
View details for DOI 10.1097/GCO.0000000000000741
View details for PubMedID 34459793
Inflammatory bowel disease and the impact on rates of chorioamnionitis, sepsis, and severe maternal morbidity
MOSBY-ELSEVIER. 2021: S441–S442
View details for Web of Science ID 000621547401249
Use of Remdesivir for Pregnant Patients with Severe Novel 2019 Coronavirus Disease.
American journal of obstetrics and gynecology
View details for DOI 10.1016/j.ajog.2020.08.001
View details for PubMedID 32771381
The obstetric research landscape: a cross-sectional analysis of clinical trials from 2007-2020.
American journal of obstetrics & gynecology MFM
Obstetric complications impact over a third of women globally, but are underrepresented in clinical research. Little is known about the comprehensive obstetric clinical trial landscape, how it compares to other fields, or factors associated with the successful completion of obstetric trials.To characterize obstetric clinical trials registered on ClinicalTrials.gov with the primary objective of identifying features associated with early discontinuation and results reporting.This is a cross-sectional study with descriptive, logistic regression and cox regression analyses of clinical trials registered on ClinicalTrials.gov. Our primary exposure variables were trial focus (obstetric or non-obstetric) and trial funding (industry, United States government or academic). We conducted additional exploratory analyses of other trial features including design, enrollment, and therapeutic focus. We examined the associations of exposure variables and other trial features with two primary outcomes: early discontinuation and results reporting.We downloaded data for all studies (n=332,417) registered on ClinicalTrials.gov from October 1, 2007 to March 9, 2020 from the Aggregate Analysis of the ClinicalTrials.gov database. We excluded studies with a non-interventional design (n=63,697) and those registered before October 1, 2007 (n=45,209). 4,276 (1.9%) obstetric trials (i.e. interventional studies), and 219,235 (98.1%) non-obstetric trials were compared. Among all trials, 2.8% of academic-funded trials, 1.9% of United States government-funded trials, and 0.4% of industry-funded trials focused on obstetrics. The quantity of obstetric trials increased over time (10.8% annual growth rate). Compared to non-obstetric trials, obstetric trials had a greater risk of early discontinuation (adjusted hazard ratio 1.40, 95% confidence interval: 1.21 to 1.62, p<0.0001) and similar odds of results reporting (adjusted odds ratio 0.89, 95% confidence interval: 0.72 to 1.10, p=0.19). Among obstetric trials funders after controlling for confounding variables, United States government-funded trials were at lowest risk of early discontinuation (US government adjusted hazard ratio 0.23, 95% confidence interval 0.07 to 0.69, p=0.009, industry reference; academic adjusted hazard ratio 1.04, 95% confidence interval 0.62 to 1.74, p=0.88). Academic-funded trials had the lowest odds of results reporting after controlling for confounding variables (academic institutions adjusted odds ratio 0.39, 95% confidence interval 0.22 to 0.68, p=0.0009; industry reference; US government adjusted odds ratio 1.06 95% confidence interval 0.53 to 2.09, p=0.87).Obstetric trials represent only 1.9% of all clinical trials in ClinicalTrials.gov and have comparatively poor completion. All stakeholders should commit to increasing the number of obstetric trials and improving their completion and dissemination to ensure clinical research reflects the obstetric burden of disease and advances maternal health.
View details for DOI 10.1016/j.ajogmf.2020.100253
View details for PubMedID 33043288
View details for PubMedCentralID PMC7537600
Relationships of uterine fibroids to racial/ethnic disparities in severe maternal morbidity
MOSBY-ELSEVIER. 2020: S170–S171
View details for DOI 10.1016/j.ajog.2019.11.263
View details for Web of Science ID 000504997300247
Early discontinuation and results reporting in obstetric clinical trials: An analysis of 3317 clinicaltrials.gov investigations
MOSBY-ELSEVIER. 2020: S55–S56
View details for DOI 10.1016/j.ajog.2019.11.082
View details for Web of Science ID 000504997300067
The obstetric clinical trial landscape: a characterization of clinicaltrials.gov investigations from 2007-2018
MOSBY-ELSEVIER. 2020: S459–S460
View details for DOI 10.1016/j.ajog.2019.11.739
View details for Web of Science ID 000504997301052
Antepartum anemia and racial/ethnic disparities in blood transfusion in california
MOSBY-ELSEVIER. 2020: S304
View details for DOI 10.1016/j.ajog.2019.11.480
View details for Web of Science ID 000504997300463